Effect of Glycine on Helicobacter Pylori in Vitro

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2004 Sep 25

PMID 15388434

Citations 19

Authors

Masaaki Minami

Takafumi Ando

Shin-Nosuke Hashikawa

Keizo Torii

Tadao Hasegawa

Dawn A Israel

Kenji Ina

Kazuo Kusugami

Hidemi Goto

Michio Ohta

Affiliations

Soon will be listed here.

Abstract

Glycine is the simplest amino acid and is used as a metabolic product in some bacteria. However, an excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The effect of glycine on Helicobacter pylori is not precisely known. The present study was conducted to investigate (i) the effect of glycine on clarithromycin (CLR)-resistant and -susceptible strains of H. pylori, (ii) the effect of glycine in combination with amoxicillin (AMX), and (iii) the postantibiotic effect (PAE). The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains. We constructed isogenic CLR-resistant mutant strains by natural transformation and investigated the difference between clinical wild-type strains and isogenic mutants. There were no differences in the MICs between CLR-resistant and -susceptible strains or between clinical wild-type and mutant strains. The combination of AMX and glycine showed synergistic activity, with the minimum bactericidal concentration of AMX with glycine decreasing to 1/10 that of AMX alone. Glycine showed no PAE against H. pylori. These results suggest that glycine may be a useful antimicrobial agent against H. pylori not only alone but also in combination with antibacterial drugs for the treatment of H. pylori-associated diseases. Glycine may represent a component of a new type of eradication therapy for CLR-resistant H. pylori.

Citing Articles

Determining the minimal inhibitory concentration of glycine against indigenous strain of Helicobacter pylori isolated from gastric biopsies.

Javanbakhat P, Hosseinali Z, Nemati R, Yazdanbod A, Teimourpour R Indian J Gastroenterol. 2024; .

PMID: 39367953 DOI: 10.1007/s12664-024-01695-y.

Impact of Glycine Powder Air-Abrasive Debridement on Peri-Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes.

Partido B, Saraswat S, Kumar P Clin Oral Implants Res. 2024; 36(1):82-91.

PMID: 39340233 PMC: 11701969. DOI: 10.1111/clr.14361.

Liposomal Drug Delivery against Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.

Alam M, Paget T, Yussuf Moosa N, Alghurairy H, Elkordy A Pharmaceutics. 2024; 16(9).

PMID: 39339161 PMC: 11435436. DOI: 10.3390/pharmaceutics16091123.

Camel urine as a potential source of bioactive molecules showing their efficacy against pathogens: A systematic review.

Amina R, Habiba R, Abouddihaj B Saudi J Biol Sci. 2024; 31(5):103966.

PMID: 38495380 PMC: 10940778. DOI: 10.1016/j.sjbs.2024.103966.

Evaluation of glycyl-arginine and lysyl-aspartic acid dipeptides for their antimicrobial, antibiofilm, and anticancer potentials.

Sevim Akan H, Sahal G, Karaca T, Gurpinar O, Maras M, Dogan A Arch Microbiol. 2023; 205(12):365.

PMID: 37906313 DOI: 10.1007/s00203-023-03724-4.

References

Graham D . Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol. 1991; 6(2):105-13. DOI: 10.1111/j.1440-1746.1991.tb01448.x. View

Ando T, Xu Q, Torres M, Kusugami K, Israel D, Blaser M . Restriction-modification system differences in Helicobacter pylori are a barrier to interstrain plasmid transfer. Mol Microbiol. 2000; 37(5):1052-65. DOI: 10.1046/j.1365-2958.2000.02049.x. View

Marshall B, Warren J . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390):1311-5. DOI: 10.1016/s0140-6736(84)91816-6. View

Hammes W . The LD-carboxypeptidase activity in Gaffkya homari. The target of the action of D-amino acids or glycine on the formation of wall-bound peptidoglycan. Eur J Biochem. 1978; 91(2):501-7. DOI: 10.1111/j.1432-1033.1978.tb12703.x. View

Hammes W, Schleifer K, Kandler O . Mode of action of glycine on the biosynthesis of peptidoglycan. J Bacteriol. 1973; 116(2):1029-53. PMC: 285483. DOI: 10.1128/jb.116.2.1029-1053.1973. View

Ando T, Israel D, Kusugami K, Blaser M . HP0333, a member of the dprA family, is involved in natural transformation in Helicobacter pylori. J Bacteriol. 1999; 181(18):5572-80. PMC: 94075. DOI: 10.1128/JB.181.18.5572-5580.1999. View

Holo H, Nes I . High-Frequency Transformation, by Electroporation, of Lactococcus lactis subsp. cremoris Grown with Glycine in Osmotically Stabilized Media. Appl Environ Microbiol. 1989; 55(12):3119-23. PMC: 203233. DOI: 10.1128/aem.55.12.3119-3123.1989. View

Kato M, Yamaoka Y, Kim J, Reddy R, Asaka M, Kashima K . Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000; 44(8):2214-6. PMC: 90045. DOI: 10.1128/AAC.44.8.2214-2216.2000. View

Yakoob J, Fan X, Hu G, Liu L, Zhang Z . Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J Gastroenterol Hepatol. 2001; 16(9):981-5. DOI: 10.1046/j.1440-1746.2001.02553.x. View

10.

Takeuchi H, Shirai M, Akada J, Tsuda M, Nakazawa T . Nucleotide sequence and characterization of cdrA, a cell division-related gene of Helicobacter pylori. J Bacteriol. 1998; 180(19):5263-8. PMC: 107570. DOI: 10.1128/JB.180.19.5263-5268.1998. View

11.

Labenz J, Gyenes E, Ruhl G, Borsch G . Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993; 88(4):491-5. View

12.

Logan R, Gummett P, Hegarty B, Walker M, Baron J, Misiewicz J . Clarithromycin and omeprazole for Helicobacter pylori. Lancet. 1992; 340(8813):239. DOI: 10.1016/0140-6736(92)90502-t. View

13.

Tsuzuki T, Ina K, Ohta M, Hasegawa T, Nagasaka T, Saburi N . Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. Aliment Pharmacol Ther. 2002; 16 Suppl 2:217-28. DOI: 10.1046/j.1365-2036.16.s2.23.x. View

14.

Sung J, Chung S, Ling T, Yung M, Leung V, Ng E . Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995; 332(3):139-42. DOI: 10.1056/NEJM199501193320302. View

15.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

16.

Hassan I, STARK R, Greenman J, Millar M . Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J Antimicrob Chemother. 1998; 42(5):661-3. DOI: 10.1093/jac/42.5.661. View

17.

Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S . Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995; 345(8965):1591-4. DOI: 10.1016/s0140-6736(95)90113-2. View

18.

Horii T, Kimura T, Nada T, Shibayama K, Ohta M . beta-Lactamase inhibitors have antibacterial activities against Helicobacter pylori. J Infect Chemother. 2002; 5(4):206-207. DOI: 10.1007/s101560050036. View

19.

Hojo M, Miwa H, Nagahara A, Sato N . Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol. 2001; 36(7):690-700. DOI: 10.1080/003655201300191941. View

20.

Strominger J, BIRGE C . NUCLEOTIDE ACCUMULATION INDUCED IN STAPHYLOCOCCUS AUREUS BY GLYCINE. J Bacteriol. 1965; 89:1124-7. PMC: 277607. DOI: 10.1128/jb.89.4.1124-1127.1965. View